Compare Orion Office REIT Inc (ONL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs BIO-TECHNE Corp — how do they compare? Orion Office REIT Inc trades at $2.62 (market cap $151.74M), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 73.5× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3%). Which is the better fit depends on your goals.
| ONL | TECH | |
|---|---|---|
Market Cap | $151.74M | $11.16B |
Sector | Real Estate | Health |
52-Week High | $3.04 | $72.12 |
52-Week Low | $1.93 | $43.31 |
Enterprise Value | $635.39M | $11.24B |
Dividend Yield | 3% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.67, up 1.52% with mixed technical signals showing bullish oscillators but bearish moving averages. The company faces significant fundamental challenges with revenue declining from $208M in 2022 to $147.65M in 2025 and deep net losses widening to -$139.31M. However, strategic reviews with Wells Fargo and JPMorgan and recent refinancing extensions provide some stability amid ongoing portfolio repositioning toward dedicated use assets.
The outlook remains challenging with persistent losses and declining revenue, though the strategic review and deleveraging progress offer potential catalysts. Key risks include execution of asset sales, office market headwinds, and negative cash flow from operations. Analyst sentiment is divided with 50% buy and 50% hold ratings, reflecting uncertainty about the turnaround strategy's success.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
